FDA規制化合物
この化合物はFDA承認または規制されています。有効な処方箋なしでの購入は連邦法違反となる可能性があります。管轄区域のすべての法的要件を確認してください。
Liraglutide
Victoza / Saxenda
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, sharing 97% homology with native human GLP-1. It is FDA-approved as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. As a once-daily injection, it was the first long-acting GLP-1 analog to achieve widespread clinical use and served as the predecessor to semaglutide.
作用機序
GLP-1 receptor agonist with 97% homology to native GLP-1. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.
研究プロトコル
研究目的のみで使用。医療アドバイスではありません。
Weight management protocols use up to 3.0mg daily with weekly 0.6mg dose escalation.
研究ノート
Clinical Research Status
Liraglutide holds full FDA approval for two indications: type 2 diabetes (Victoza, approved 2010) and obesity (Saxenda, approved 2014). The LEADER cardiovascular outcomes trial demonstrated a 13% reduction in major adverse cardiovascular events. It remains widely prescribed though newer weekly agents are increasingly preferred.
Key Published Findings
The SCALE trials demonstrated 5-8% mean body weight loss versus placebo across multiple populations. Liraglutide has been shown to reduce HbA1c by 1.0-1.5% in type 2 diabetes, with additional benefits in beta-cell preservation. Post-marketing data from over a decade of use provides one of the most robust safety databases among GLP-1 agonists.
Safety Profile
The most common adverse effects are gastrointestinal: nausea, vomiting, and diarrhea, typically diminishing over 4-8 weeks of dose titration. A boxed warning exists for medullary thyroid carcinoma risk based on rodent studies, though human epidemiological data has not confirmed this risk. Pancreatitis cases have been reported rarely, and the drug is contraindicated in patients with personal or family history of MTC.
Comparison to Related Compounds
Compared to semaglutide, liraglutide requires daily rather than weekly injection and produces less weight loss (approximately 5-8% vs 15-17% body weight). It has a shorter half-life of 13 hours versus semaglutide's 7-day half-life, resulting in lower steady-state exposure. However, its longer track record provides greater long-term safety confidence for some clinicians.
Community Observations
Many users report that liraglutide's daily dosing allows more flexible appetite control timing compared to weekly injectables. The gradual dose titration schedule (0.6mg to 3.0mg over 4-5 weeks for obesity) helps mitigate GI side effects. Some practitioners still prefer it for patients who want the option to pause treatment quickly due to its shorter duration of action.
半減期
~13 hours
再構成
Pre-filled pen (no reconstitution)
保存
乾燥粉末
Refrigerate 2-8C before first use.
再溶解
Room temperature or refrigerate. Use within 30 days.
米国法的状況
また知られる名前
最新の研究
Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.
よくある質問
Liraglutideとは何ですか?
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, sharing 97% homology with native human GLP-1. It is FDA-approved as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. As a once-daily injection, it was the first long-acting GLP-1 analog to achieve widespread clinical use and served as the predecessor to semaglutide.
Liraglutideはどのように作用しますか?
GLP-1 receptor agonist with 97% homology to native GLP-1. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.
Liraglutideの米国での規制状況は?
FDA-approved (Rx only)
Liraglutideの半減期は?
~13 hours
Liraglutideの別名は?
Victoza, Saxenda
ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。
完全な免責事項を読む